Saw palmetto extract: Newest (and Oldest) treatment alternative for men with symptomatic benign prostatic hyperplasia

Urology

Volumn 53, Issue 3, 1999, Pages 457-461

  Marks, Leonard S ^a,b   Tyler, Varro E ^a,b  

^a Univ of California   (United States)

^b PURDUE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFLAMMATORY ACTIVITY; DRUG EFFICACY; DRUG MECHANISM; DRUG MONITORING; DRUG PREFERENCE; DRUG SAFETY; EDITORIAL; HERBAL MEDICINE; HUMAN; PHYTOTHERAPY; PRIORITY JOURNAL; PROSTATE HYPERTROPHY; SABAL;

ANDROGEN ANTAGONISTS; HUMANS; MALE; PLANT EXTRACTS; PROSTATIC HYPERPLASIA; SERENOA;

EID: 0033104374     PISSN: 00904295     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0090-4295(98)00635-9     Document Type: Editorial

References (29)

1. Nickel JC: Placebo therapy of benign prostatic hyperplasia: A 25-month study (Canadian PROSPECT study group). Br J Urol 81: 383-387, 1998.
2. Brown WA: The placebo effect. Sci Am 278: 90-95, 1998.
3. Lieber M: Pharmacologic therapy for prostatism. Mayo Clin Proc 73: 590-596, 1998.
4. Clary M: Berry rich in hype becomes a cash crop. Los Angeles Times. September 1, 1997, Section A, p 6.
5. Monmaney T, and Roan S: Alternative medicine, hope or hype: First in a series. Los Angeles Times. August 30, 1998, Section A, p 1.
6. Lowe FC, and Ku JC: Phytotherapy in treatment of benign prostatic hyperplasia: A critical review. Urology 48: 12-20, 1996.
7. Carraro JC, Raynaud JP, Koch G, et al: Comparison of phytotherapy (Permixon) with finasteride in the treatment of benign prostate hyperplasia: A randomized international study of 1098 patients. Prostate 29: 231-240, 1996.
8. Bach D, and Ebeling L: Long-term drug treatment of benign prostatic hyperplasia: Results of a prospective 3-year multicenter study using Sabal extract IDS 89. Phytomedicine 3: 105-111, 1996.
9. Lowe F, Robertson C, Roehrborn CG, et al: Meta-analysis of clinical trials of Permixon (abstract). J Urol 159(suppl): 257, 1998.
10. Gerber GS, Zagaja GP, Bales GT, et al: Saw palmetto (Serenoa repens) in men with lower urinary tract symptoms: Effects on urodynamic parameters and voiding symptoms. Urology 51: 1003-1007, 1998.
11. Plosker GL, and Brogden RN: Serenoa repens (Permixon): A review of its pharmacology and therapeutic efficacy in benign prostatic hyperplasia. Drugs Aging 9: 379-395, 1996.
12. Delos S, Iehle C, Martin PM, et al: Inhibition of the activity of "basic" 5-alpha-reductase (type 1) detected in DU 145 cells and expressed in insect cells. J Steroid Biochem Mol Biol 48: 347-352, 1994.
13. Iehle C, Delos S, Guirou O, et al: Human prostatic steroid 5-alpha-reductase isoforms - A comparative study of selective inhibitors. J Steroid Biochem Mol Biol 54: 273-279, 1995.
14. Weisser H, Tunn S, Behnke B, et al: Effects of the sabal serrulata extract IDS 89 and its subfractions on 5-alpha-reductase activity in human benign prostatic hyperplasia. Prostate 28: 300-306, 1996.
15. Weisser H, Behnke B, Helpap B, et al: Enzyme activities in tissue of human benign prostatic hyperplasia after three months' treatment with the Sabal serrulata extract IDS 89 (Strogen) or placebo. Eur Urol 31: 97-101, 1997.
16. Rhodes L, Primka RL, Berman C, et al: Comparison of finasteride (Proscar), a 5-alpha reductase inhibitor, and various commercial plant extracts in in vitro and in vivo 5-alpha reductase inhibition. Prostate 22: 43-51, 1993.
17. Strauch G, Perles P, Vergult G, et al: Comparison of finasteride (Proscar) and Serenoa repens (Permixon) in the inhibition of 5-alpha reductase in healthy male volunteers. Eur Urol 26: 247-252, 1994.
18. di Silverio F, D'Eramo G, Lubrano C, et al: Evidence that Serenoa repens extract displays an antiestrogenic activity in prostatic tissue of benign prostatic hypertrophy patients. Eur Urol 21: 309-314, 1992.
19. Levin JS, Glass TA, Kushi LH, et al: Quantitative methods in research on complementary and alternative medicine: A methodological manifesto. Med Care 35: 1079-1094, 1997.
20. Berman BM, and Larson DB: Alternative Medicine: Expanding Medical Horizons. A Report to the National Institutes of Health on Alternative Medical Systems and Practices in the United States. NIH Publication No. 94-066, Washington, D.C., Government Printing Office, 1994.
21. Eisenberg DM, Kessler RC, Foster C, et al: Unconventional medicine in the United States. N Engl J Med 328: 246-283, 1993.
22. Gerber GS, Bales GT, Kirsh E, et al: Medicinal botanicals in the treatment of lower urinary tract symptoms (LUTS): A demographic analysis of awareness and use at the University of Chicago (abstract). J Urol 159(suppl): 334, 1998.
23. Astin JA: Why patients use alternative medicine: Results of a national study. JAMA 279: 1548-1553, 1998.
24. Wetzel MS, Eisenberg DM, and Kaptchuk TJ: Courses involving complementary and alternative medicine at U.S. medical schools. JAMA 280: 784-787, 1998.
25. Fontanarosa PB, and Lundberg GD: Complementary, alternative, unconventional, and integrative medicine: Call for papers for the annual coordinated theme issues of the AMA journals. JAMA 278: 2111-2112, 1997.
26. Angell M, and Kassirer JP: Alternative medicine - The risks of untested and unregulated remedies. N Engl J Med 339: 839-841, 1998.
27. Herbal roulette. Consumer Rep 11: 698-704, 1995.
28. Lowe FC, Dreikorn K, Borkowski A, et al: Review of recent placebo-controlled trials utilizing phytotherapeutic agents for treatment of BPH. Prostate 37: 187-193, 1998.
29. Wilt TJ, Ishani A, Stark G, et al: Saw palmetto extracts for treatment of benign prostatic hyperplasia. A systematic review. JAMA 280: 1604-1609, 1998.